Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03755739 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion date: Nov 1, 2033 to Nov 1, 2036v5
  2. Interventions: Checkpoint inhibitor (CPI) such as Pembrolizumab (Drug) to Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy (Drug)
    • Study description expanded, about 6 words
    • Study title expanded, about 2 words
    v4
  3. Primary completion date: Nov 1, 2020 to Nov 1, 2033v3 Show 7 more changesShow less
    • Primary endpoints: 1 to 2
    • Study completion date: Nov 1, 2021 to Nov 1, 2033
    • Interventions: Pembrolizumab (Drug) to Checkpoint inhibitor (CPI) such as Pembrolizumab (Drug)
    • Eligibility criteria shortened, about 71 words
    • Secondary endpoints: 3 to 4
    • Study description expanded, about 3 words
    • Study title expanded, about 1 word
  4. Phase: Not applicable to Phase 2/3
    • Study description shortened, about 98 words
    • Study title shortened, about 4 words
    v2
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This trial was designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody and/or CTLA4 antibody ipilimumab plus chemotherapeutic drug and to compare their differences.
Trial Details
NCT Number NCT03755739
Lead Sponsor Second Affiliated Hospital of Guangzhou Medical University
Conditions
(from sponsor)		 Hepatocarcinoma, Lung Cancer, Melanoma, Renal Cancer, Head and Neck Cancer, Pancreas Cancer, Ovarian Cancer, Colo-rectal Cancer +2 more
Related terms Breast Neoplasms, Carcinoma, Hepatocellular, Colonic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Uterine Cervical Neoplasms
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov